These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 37570646

  • 1. The Anticancer Effect of Napabucasin (BBI608), a Natural Naphthoquinone.
    Shao Z, Wang H, Ren H, Sun Y, Chen X.
    Molecules; 2023 Jul 27; 28(15):. PubMed ID: 37570646
    [Abstract] [Full Text] [Related]

  • 2. Bioactivation of Napabucasin Triggers Reactive Oxygen Species-Mediated Cancer Cell Death.
    Froeling FEM, Swamynathan MM, Deschênes A, Chio IIC, Brosnan E, Yao MA, Alagesan P, Lucito M, Li J, Chang AY, Trotman LC, Belleau P, Park Y, Rogoff HA, Watson JD, Tuveson DA.
    Clin Cancer Res; 2019 Dec 01; 25(23):7162-7174. PubMed ID: 31527169
    [Abstract] [Full Text] [Related]

  • 3. Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor.
    Hubbard JM, Grothey A.
    Drugs; 2017 Jul 01; 77(10):1091-1103. PubMed ID: 28573435
    [Abstract] [Full Text] [Related]

  • 4. Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells.
    Han D, Yu T, Dong N, Wang B, Sun F, Jiang D.
    J Exp Clin Cancer Res; 2019 Jul 05; 38(1):289. PubMed ID: 31277685
    [Abstract] [Full Text] [Related]

  • 5. STAT3 Inhibitor Napabucasin Inhibits Tumor Growth and Cooperates with Proteasome Inhibition in Human Ovarian Cancer Cells.
    Liu Y, Peng X, Li H, Jiao W, Peng X, Shao J, Xu Y, Wang R, Wang W, Kong D.
    Recent Pat Anticancer Drug Discov; 2021 Jul 05; 16(3):350-362. PubMed ID: 33655847
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of Tumor Cell-Tumor Microenvironment Component Interactions as Potential Predictors of Patient Response to Napabucasin.
    Chang AY, Hsu E, Patel J, Li Y, Zhang M, Iguchi H, Rogoff HA.
    Mol Cancer Res; 2019 Jul 05; 17(7):1429-1434. PubMed ID: 31043490
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of STAT3 prevents bone metastatic progression of prostate cancer in vivo.
    Thulin MH, Määttä J, Linder A, Sterbova S, Ohlsson C, Damber JE, Widmark A, Persson E.
    Prostate; 2021 Jun 05; 81(8):452-462. PubMed ID: 33822400
    [Abstract] [Full Text] [Related]

  • 8. The synergistic anticancer effects of ReoT3D, CPT-11, and BBI608 on murine colorectal cancer cells.
    Babaei A, Soleimanjahi H, Soleimani M, Arefian E.
    Daru; 2020 Dec 05; 28(2):555-565. PubMed ID: 32803686
    [Abstract] [Full Text] [Related]

  • 9. Napabucasin, a novel inhibitor of STAT3, inhibits growth and synergises with doxorubicin in diffuse large B-cell lymphoma.
    Li X, Wei Y, Wei X.
    Cancer Lett; 2020 Oct 28; 491():146-161. PubMed ID: 32798587
    [Abstract] [Full Text] [Related]

  • 10. Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
    Löcken H, Clamor C, Müller K.
    J Nat Prod; 2018 Jul 27; 81(7):1636-1644. PubMed ID: 30003778
    [Abstract] [Full Text] [Related]

  • 11. A novel series of napabucasin derivatives as orally active inhibitors of signal transducer and activator of transcription 3 (STAT3).
    Li C, Chen C, An Q, Yang T, Sang Z, Yang Y, Ju Y, Tong A, Luo Y.
    Eur J Med Chem; 2019 Jan 15; 162():543-554. PubMed ID: 30472602
    [Abstract] [Full Text] [Related]

  • 12. Molecular crosstalk between MUC1 and STAT3 influences the anti-proliferative effect of Napabucasin in epithelial cancers.
    Bose M, Sanders A, Handa A, Vora A, Cardona MR, Brouwer C, Mukherjee P.
    Sci Rep; 2024 Feb 07; 14(1):3178. PubMed ID: 38326371
    [Abstract] [Full Text] [Related]

  • 13. Napabucasin (BBI608) eliminate AML cells in vitro and in vivo via inhibition of Stat3 pathway and induction of DNA damage.
    Bi S, Chen K, Feng L, Fu G, Yang Q, Deng M, Zhao H, Li Z, Yu L, Fang Z, Xu B.
    Eur J Pharmacol; 2019 Jul 15; 855():252-261. PubMed ID: 31085238
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of STAT3 blocks protein synthesis and tumor metastasis in osteosarcoma cells.
    Zuo D, Shogren KL, Zang J, Jewison DE, Waletzki BE, Miller AL, Okuno SH, Cai Z, Yaszemski MJ, Maran A.
    J Exp Clin Cancer Res; 2018 Oct 04; 37(1):244. PubMed ID: 30286779
    [Abstract] [Full Text] [Related]

  • 15. Thermal Proteome Profiling in Zebrafish Reveals Effects of Napabucasin on Retinoic Acid Metabolism.
    Leijten NM, Bakker P, Spaink HP, den Hertog J, Lemeer S.
    Mol Cell Proteomics; 2021 Oct 04; 20():100033. PubMed ID: 33594990
    [Abstract] [Full Text] [Related]

  • 16. Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin.
    Zhang Y, Jin Z, Zhou H, Ou X, Xu Y, Li H, Liu C, Li B.
    Cancer Med; 2016 Jun 04; 5(6):1251-8. PubMed ID: 26899963
    [Abstract] [Full Text] [Related]

  • 17. STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice.
    Bitsch R, Kurzay A, Özbay Kurt F, De La Torre C, Lasser S, Lepper A, Siebenmorgen A, Müller V, Altevogt P, Utikal J, Umansky V.
    J Immunother Cancer; 2022 Mar 04; 10(3):. PubMed ID: 35301236
    [Abstract] [Full Text] [Related]

  • 18. The cancer stemness inhibitor napabucasin suppresses small cell lung cancer growth through SOX2 expression.
    Li JM, Hsu PC, Kuan FC, Shi CS, Yang CT.
    Am J Cancer Res; 2022 Mar 04; 12(10):4637-4651. PubMed ID: 36381330
    [Abstract] [Full Text] [Related]

  • 19. Discovery of a Napabucasin PROTAC as an Effective Degrader of the E3 Ligase ZFP91.
    Hanafi M, Chen X, Neamati N.
    J Med Chem; 2021 Feb 11; 64(3):1626-1648. PubMed ID: 33506674
    [Abstract] [Full Text] [Related]

  • 20. Napabucasin (BBI 608), a potent chemoradiosensitizer in rectal cancer.
    Nagaraju GP, Farran B, Farren M, Chalikonda G, Wu C, Lesinski GB, El-Rayes BF.
    Cancer; 2020 Jul 15; 126(14):3360-3371. PubMed ID: 32383803
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.